Efficacy of Initiating Sodium Glucose Co Transporter 2 Inhibitor (SGLT2I) for Treatment of Type II Diabetes Mellitus
Nasir Mahmood, Muhammad Qasim, Talal Safdar, Shazia Yousaf, Muhammad Iqbal Qasim, Amjad Ali
951
ABSTRACT
Sodium glucose co-transporter 2 (SGLT 2) inhibitors are hypoglycemic
agents that have action on kidneys. They cause increased excretion of glucose
via kidneys by reducing its absorption.
In healthy individuals,
kidneys filter almost all of the glucose and return it back into circulation,
excreting only a minimum amount in the urine. This reabsorption is facilitated
by SGLT 2 receptors which are found in early proximal tubule, with some
assistance by sodium glucose co-transporter 1 (SGLT 1).
In patients with type 2
diabetes mellitus (T2DM), activity of SGLT 2 is increased. This results in
increased absorption of glucose in the bloodcausing further hyperglycemia.
Objectives: To determine the efficacy of
initiating sodium glucose co transporter2 inhibitor (SGLT2i) in patients with
type 2 diabetes mellitus.
Study design: Descriptive, case series study
Study duration:28th
April 2020 to 27th October 2020.
Settings: Department of Medicine, Aziz Fatima
hospital, Faisalabad and Diabetes &
Endocrinology Ward of Hayatabad Medical Complex, Peshawar
Materials
& Methods: 150 patients with
T2D aged between 18 to 60 years.
Patients with pregnancy, CHF, those who had received an oral hypoglycemic medication
other than metformin for more than 14 days were excluded. All the
patients were given Dapagliflozin 10 mg once daily for 26 weeks. For evaluation
of HbA1c, blood sampleswere checked and reported by pathologist at hospital.
Efficacy was assessed after 26 weeks of treatment.
Results:In this study, participants were in the age range from 18 to 60
years with mean age of 40.77 ± 9.42 years. Eighty three patients (55.33%) were
between 18 to 40 years of age. Out of 150 patients, 93 (62.0%) were male and 57
(38.0%) were females with male to female ratio 1.6:1. In our study, efficacy of
initiating sodium glucose co transporter -2 inhibitor (SGLT2i) in patients of
type 2 diabetes mellitus was found in 65 (43.33%) patients.
Conclusion: This study concluded that “the efficacy of initiating sodium glucose
co transporter - 2 inhibitor (SGLT2i) in patients of type 2 diabetes mellitus
is quite high.”
Keywords: type 2 diabetes mellitus, sodium glucose co transporter -2 inhibitor,efficacy.
ABSTRACT
Sodium glucose co-transporter 2 (SGLT 2) inhibitors are hypoglycemic
agents that have action on kidneys. They cause increased excretion of glucose
via kidneys by reducing its absorption.
In healthy individuals,
kidneys filter almost all of the glucose and return it back into circulation,
excreting only a minimum amount in the urine. This reabsorption is facilitated
by SGLT 2 receptors which are found in early proximal tubule, with some
assistance by sodium glucose co-transporter 1 (SGLT 1).
In patients with type 2
diabetes mellitus (T2DM), activity of SGLT 2 is increased. This results in
increased absorption of glucose in the bloodcausing further hyperglycemia.
Objectives: To determine the efficacy of
initiating sodium glucose co transporter2 inhibitor (SGLT2i) in patients with
type 2 diabetes mellitus.
Study design: Descriptive, case series study
Study duration:28th
April 2020 to 27th October 2020.
Settings: Department of Medicine, Aziz Fatima
hospital, Faisalabad and Diabetes &
Endocrinology Ward of Hayatabad Medical Complex, Peshawar
Materials
& Methods: 150 patients with
T2D aged between 18 to 60 years.
Patients with pregnancy, CHF, those who had received an oral hypoglycemic medication
other than metformin for more than 14 days were excluded. All the
patients were given Dapagliflozin 10 mg once daily for 26 weeks. For evaluation
of HbA1c, blood sampleswere checked and reported by pathologist at hospital.
Efficacy was assessed after 26 weeks of treatment.
Results:In this study, participants were in the age range from 18 to 60
years with mean age of 40.77 ± 9.42 years. Eighty three patients (55.33%) were
between 18 to 40 years of age. Out of 150 patients, 93 (62.0%) were male and 57
(38.0%) were females with male to female ratio 1.6:1. In our study, efficacy of
initiating sodium glucose co transporter -2 inhibitor (SGLT2i) in patients of
type 2 diabetes mellitus was found in 65 (43.33%) patients.
Conclusion: This study concluded that “the efficacy of initiating sodium glucose
co transporter - 2 inhibitor (SGLT2i) in patients of type 2 diabetes mellitus
is quite high.”
Keywords: type 2 diabetes mellitus, sodium glucose co transporter -2 inhibitor,efficacy.